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Spinal Muscular Atrophy (SMA) is a motor neuron disease that predominantly 
affects children, with the most severe form of SMA resulting in death before the age 
of 2 years. It is an autosomal recessive disorder that leads to progressive paralysis 
and muscle atrophy due to the degeneration of lower motor neurons. Furthermore, a 
loss of the connections between motor neurons and muscle (neuromuscular 
junctions; NMJs) occurs early in the disease.  Importantly, not all motor neurons are 
equally affected. For example, in specific mouse models of SMA, there is a high 
level of NMJ loss in the abdominal muscles while NMJs within cranial muscles 
remain intact, even at late stages of disease. Prior to this study, RNAseq analysis of 
differentially vulnerable motor neurons in the Smn2B/- mouse model of SMA, and in 
wild-type mice, was carried out at a pre-symptomatic stage. In this project, there are 
two main aims. Firstly, transcriptional changes that occur between differentially 
vulnerable motor neurons were further investigated. qRT-PCR was used to detect 
transcriptional changes that occur between Smn2B/- and wild type mice and 
immunofluorescence was used to detect protein markers of transcripts that were 
altered in vulnerable motor neurons. qRT-PCR confirmed changes in Ubiquitin as 
well as transcripts associated with cell death. Immunofluorescence analysis showed 
no significant change in protein markers of DNA repair between differentially 
vulnerable motor neuron populations. Secondly, the activation of a cell death 
pathway in a mouse model of SMA was investigated. For this aim, the Smn2B/- mouse 
line was re-derived and preliminary phenotypic assessment was preformed. The re-
derived model displays similar features to the original Smn2B/- mouse model of SMA. 
In addition, the incidence and timing of cell death pathway activation was 
investigated by qRT-PCR. This showed an up-regulation of transcripts involved in 
cell death pre-symptomatically. Up-regulation of these transcripts at this time point 
suggests that the activation of cell death pathways may contribute to motor neuron 
degeneration and therefore warrants further investigation.  
  
Natalie	  L	  Courtney	   	   The	  University	  of	  Edinburgh	  




Motor neurons are long cells that connect the spinal cord to muscles, instructing the 
muscles to contract. In motor neuron diseases, like Spinal Muscular Atrophy (SMA), 
these cells breakdown and the connection to the muscle (neuromuscular junction) is 
destroyed. In SMA, some motor neurons in the body are resistant, and even at a late 
stage in the disease the neuromuscular junction does not breakdown. To date, it is not 
known why some motor neurons are resistant. Prior to this project, work found 
differences between motor neurons of healthy mice and SMA-like mice. It also, 
found differences between the motor neurons that breakdown and the motor neurons 
that don’t. In this project, we wanted to confirm these differences. In addition, we 
found that in the motor neurons that breakdown, the switch that tells them to die has 
been turned on early, before there appears to be anything physically wrong with the 
cell. Perhaps, if the turning on of this switch is delayed, the breakdown of the motor 
neuron will be postponed. We suggest this idea should be investigated further.  
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Chapter 1: Introduction 
	  
Spinal Muscular Atrophy (SMA) is a devastating motor neuron disease that affects 
primarily children. It is an autosomal recessive disorder that leads to progressive 
paralysis and muscle atrophy due to the degeneration of lower motor neurons. With a 
carrier frequency of 1 in 35 and an incidence of 1:6000, it is the most common 
genetic cause of infant mortality.1 The most severe form of SMA results in death 
before the age of 2 years however the levels of severity that manifest can vary 
substantially.2 Despite this debilitating and distressing disorder affecting a relatively 
high population there is, to date, no known treatment or cure for SMA.  
 
SMA is caused by a mutation or deletion of the Survival Motor Neuron 1 (SMN1) 
gene resulting in a decrease in Survival Motor Neuron (SMN) protein.3,4 As well as 
SMN1, humans possess another SMN gene, SMN2, which has an alternative pre-
mRNA splicing pattern due to a C-T transition in exon 7.5 Therefore, the majority of 
SMN2 product is a reduced length, short lived and non-functional SmnΔ7 protein, 
with only 10-15% of SMN2 product being full length SMN.6,7 There is variation in 
the number of copies of SMN2 within the human genome and since SMN2 copy 
number is proportional to the level of full length SMN produced, the copy number is 
a determinant of disease severity.8  
	  
Although SMN is a ubiquitous protein, motor neurons are selectively vulnerable 
when SMN is reduced and they degenerate as a result.9 The reasons for this selective 
vulnerability of motor neurons are still unclear but perhaps a cellular threshold exists 
and SMN levels in SMA are lower than that required by motor neurons.4,10 This 
theory is supported by reports that severe SMA patients, who will have the lowest 
levels of SMN protein, can present with heart defects that are not observed in 
patients with less severe forms of SMA, who will have increased levels of SMN 
protein.11 This suggests that the heart can also be susceptible to low SMN but its 
threshold is greater than the threshold of motor neurons.4 The degeneration of motor 
neurons is initially apparent at the neuromuscular junctions (NMJs), the connection 
between the axon of a lower motor neuron (pre-synaptic terminal) and the endplate 
of a muscle fiber (post-synaptic terminal).9 There have been reports of various 
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abnormalities at these junctions in SMA; they fail to mature and as the disease 
progresses there is an accumulation of neurofilaments (NFs) at the pre-synaptic 
terminal as well as denervation of endplates and pre-synaptic terminal sprouting.9,12 
 
Further to this selective vulnerability, specific subsets of motor neurons are more 
vulnerable to low SMN than others and while some degenerate others are resistant 
and remain in tact, even at the end stage of the disease.9,13,14 For example, motor 
neurons that supply muscles of the abdomen degenerate while motor neurons 
supplying cranial muscles do not.15,16 Again, the reasons for this are still unclear. 
Murray et. al. (Acta Neuropathol. Commun., In Press) performed transcriptional 
analysis of these differentially vulnerable motor neurons to address why some are 
more susceptible to degeneration.15 They asked two main questions (Figure 1). 
Firstly, what transcriptional changes occur when SMN is reduced? For this they 
compared SMA mouse model motor neurons to wild type mice motor neurons. In 
their comparison they used two distinct motor neuron populations, the thoracic spinal 
cord motor neurons, that supply abdominal muscles and are vulnerable in SMA, and 
brainstem motor neurons, that supply cranial muscle and are resistant in SMA 
(Figure 1: blue arrows). By having two comparisons, they were able to filter the 
transcriptional changes that occurred in both, lowering the number of transcriptional 
changes that were most likely caused by reduced SMN and were therefore of interest. 
Secondly, they asked what transcriptional changes occur in vulnerable motor neurons 
that may make them degenerate? To answer the second question they compared the 
vulnerable SMA motor neurons that degenerate to motor neurons that don’t 
degenerate. Those that don’t degenerate and were used as comparisons were resistant 
SMA motor neurons and wild type vulnerable motor neurons (Figure 1: red arrows). 
Again, they filtered for transcriptional changes that were common in the two 
comparisons.  
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Prior to the work by Murray et. al. (Acta Neuropathol. Commun., In Press), other 
studies had carried out transcriptional analysis on SMA mouse models. Zhang et. al. 
(2008) compared the transcriptional profiles of the spinal cords, as well as the brain 
and kidneys, of severe SMA mouse models to control mice, by microarray.17 This 
may provide information of transcripts altered by a reduction in SMN however, it 
does not shed light on why motor neurons in SMA are differentially vulnerable. 
Furthermore, microarray analysis is less accurate and sensitive to transcriptional 
changes than RNAseq.18 In comparison, Staroploi et. al. (2015) used RNAseq 
analysis rather than microarray but still only compared the profiles of SMA mouse 
model and control tissue.19 However, they did analyse the transcriptional profiles at 
various time points, which spanned pre-symptomatic and symptomatic stages. This 
aimed to account for transcriptional changes that occur due to developmental 
progression. Nevertheless, the work by Murray et. al. is unique. They compare very 
different and distinct motor neuron populations in an SMA mouse model and wild 
type mice and by screening for common transcriptional changes that occurred in two 
screens, both of which could answer the same question, they dramatically reduced 
the number of transcripts that could be important in causing the disease pathology. In 
addition, they look at the transcriptional profiles of these motor neuron populations 
Figure 1: A comparison of differentially vulnerable motor neurons carried out by 
Murray et. al. Blue arrows: WTr and SMAr motor neurons and WTv and SMAv motor 
neurons were compared to discover transcripts that are altered by a reduction in Smn. 
Red arrows: SMAv and Wtv motor neurons and SMAv and SMAr motor neurons were 
compared to discover alterations in transcripts that may provide resistance to 
degeneration. (Diagram adapted from Murray et. al.; WTr – Wild type resistant, WTv – 
Wild type vulnerable, SMAr – SMA model resistant, SMAv – SMA model vulnerable) 
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at a pre-symptomatic time point, before the SMA mouse model is displaying any 
pathological markers of SMA.  In the Smn2B/- mouse model of SMA, which was used 
in their work, this time point was P10.20 Therefore, the work by Murray et. al. gives 
an insight into possible genetic changes that occur in mouse models of SMA that 
could influence the onset of pathology.  
 
There are a number of mouse models of SMA that vary in their severity.  The Smn2B/- 
mouse model of SMA is an intermediate mouse model of SMA that traditionally has 
a lifespan of approximately 28 days.20 Mice lack the SMN2 gene, which is found 
only in humans and therefore the SMA phenotype of this model is established 
through the genetic modification of the murine Smn gene. The Smn2B allele of the 
gene acts like SMN2, due to a mutation within exon 7, and when expressed on a null 
background creates a mouse with a phenotype representative of SMA.21 The null 
background is created by inserting a neomycin cassette within exon 2 and is 
embryonic lethal without the addition of genetic substitutions that can produce at 
least a little SMN protein.22 Another, more severe mouse model of SMA is the Smn-/-
;SMN2(tg/0) model, which has a lifespan of 10 days.23 This mouse model of SMA is 
created through the addition of SMN2 onto a null background however, this null 
background is created by inserting a cassette into exon 7 rather than exon 2.23 
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In this project, I had the following aims: 
 
Aim 1: Investigating transcriptional differences between differentially vulnerable 
motor neurons 
 
Firstly, I aimed to detect transcriptional changes that were identified by RNAseq by 
either qRT-PCR or immunofluorescence. qRT-PCR was used to detect 
transcriptional changes that occur in the Smn2B/- mouse model of SMA compared to 
wild type motor neurons. Immunofluorescence was used to detect protein markers of 
transcripts that were altered in vulnerable motor neurons compared with resistant 
motor neurons. 
 
Aim 2: Re-deriving the Smn2B/- mouse model for investigation into cell death 
pathway activation 
 
Secondly, I aimed to re-derive the Smn2B/- mouse model of SMA in order to 
investigate cell death pathway activation. This SMA mouse model was created by 
crossing Smn2B/+ mice, on a C57BL6J background, with Smn+/- mice, on a FVB 
background. This Smn2B/- mouse model was characterized by analyzing their 
phenotypic features, weight trends, NMJ abnormalities and cell death transcripts. 
Due to an early up-regulation of transcripts involved in cell death, these mice were to 
be treated with Pifithrin-𝛼, a drug that inhibits P53, and qRT-PCR was to be used to 
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The SMA mouse models used include the intermediate model, Smn2B/-, and the 
severe model, Smn-/-;SMN2(tg/0). Smn2B/- mice were established in our laboratory 
(please see results for establishment of colony, Figure 14). Smn2B/+ mice (imported 
from the Kothary Laboratory, University of Ottawa) were interbred with wild type 
C57Bl6J mice to produce Smn2B/+ mice for subsequent breeding.  Smn+/- mice were 
kindly provided by Prof Tom Gillingwater.  Smn2B/+ and Smn+/- mice were interbred 
to produce Smn2B/- mice alongside littermates (Smn+/+; Smn+/-; Smn2B/+) all of which 
were phenotypically normal.  Wild type littermates (Smn+/+) were used as controls. 
These breeding pairs were maintained at the University of Edinburgh animal 
facilities in IVC caging. Smn-/-; SMN2(tg/0) mice were kindly provided by Prof Tom 
Gillingwater. Breeding pairs of Smn-/-;SMN2(tg/tg) and Smn+/-;SMN2(0/0) mice were 
again maintained at the University of Edinburgh animal facilities. Heterozygous 
littermates  (Smn+/-;SMN2(tg/0)) were used as controls. 
 
All mice were sacrificed by an overdose of anaesthetic (IsoFlo, Abbott, Québec, 
Canada). All procedures were carried out in accordance with the procedures 
approved and licenced by the Home Office, United Kingdom. Mice for qRT-PCR 
analysis were sacrificed at a pre-symptomatic time point (P10 for Smn2B/- mice, P2 
for Smn+/-;SMN2(tg/0)). At these ages, SMA models have no apparent phenotypic 
features of the disease and are approximately the same weight and have a similar 
righting time as littermates. Wild type mice were sacrificed at P10, the age at which 
the Smn2B/- mice are pre-symptomatic. The re-derived Smn2B/- mice were sacrificed at 
P7, pre-symptomatic, and P20, late symptomatic.  
 
PCR for Genotyping 
 
DNA was extracted from tail tips by digesting the tissue in TTLB (Tail Tip Lysis 
Buffer; 0.5M EDTA, 1M Triz-HCL, 1M NaCL, 10% SDS, ddH2O) and Proteinase K 
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(1mg/ml) overnight at 55oC. DNA was precipitated in 500  𝜇 l isopropanol and 
washed in ethanol before suspending in 200𝜇 l of distilled water to give a 
concentration of approximately 200ng/𝜇l. 
 
To establish which mice carried the Smn2B allele, PCR was preformed using the 
Invitrogen Taq polymerase kit and a forward (5’-AACTCCGGGTCCTCCTTCCT-
3’) and reverse (5’-TTTGGCAGACTTTAGCAGGGC-3’) primer. The following 
temperature cycling protocol was used: 
Step 1:  94oC for  3 minutes 
Step 2:  94oC for 45 seconds 
Step 3:  58oC for 45 seconds 
Step 4:  72oC for 45 seconds 
Repeat cycles 2-4 35 times 
Step 5:  72oC for  5 minutes 
Hold at 4oC 
 
To distinguish Smn+/- from Smn+/+ mice, PCR was preformed using the GoTaq Flexi 
DNA polymerase kit, a forward primer (5’-ATAACACCACTCTTACTC-3’) and 
two reverse primers  (5’-GTAGCCGTGATGCCATTGTCA-3’; 5’-
AGCCTGAAGAACGAGATCAGC-3’). The following temperature cycling protocol 
was used: 
Step 1:  94oC for  2 minutes 
Step 2:  94oC for 30 seconds 
Step 3:  58oC for 30 seconds 
Step 4:  68oC for  1 minute 
Repeat cycles 1-4 35 times 
Step 5:  72oC for  5 minutes 
Hold at 8oC 
 
Subsequently, gel electrophoresis separated DNA fragments and allowed the 
visualisation of the various genotypes (Please see Figure 15 in results for genotyping 
outcomes). DNA was run on a 1% agarose gel in 1X TAE at 100V for 40 minutes. 
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The whole spinal cord of recently sacrificed mice were removed, snap frozen on dry 
ice and stored at -80oC. RNA was extracted using a micro RNeasy kit (Qiagen), 
according to manufacturers instructions. Subsequently, 1ug of RNA was used to 
perform reverse transcriptase using the RT2 First Strand kit (Qiagen), as per 
manufacturers instructions. SYBR green-based qRT-PCR was preformed using Kapa 
SYBR Fast Universal (Kapa Biosystems, KK4602) and the CFX Connect Real-time 
PCR Detection system (Biorad). Custom-made primers (Sigma) were optimised 
before use (please see Figure 2 in results section) and pre-optimised primers were 
purchased from Biorad. Two housekeeping genes were used in each reaction (a 





Spinal cord and brainstems, removed from recently sacrificed mice were fixed in 4% 
Paraformaldehyde (PFA; Electron Microscopy Science) in PBS overnight and 
washed in Phosphate Buffered Saline (PBS) the following day. They were immersed 
in 30% sucrose overnight and embedded in 50% OCT compound, 15% sucrose in 
PBS. The embedded tissue was frozen on dry ice and stored at -80oC.  Frozen 
sections were cut at 12𝜇m on a cryostat (Leica) and stored at -20oC on glass slides. 
Staining was done in the Sequenza Immunostaining Centre (Fisher). Sections were 
washed in PBS, permeabilised in 0.3% Triton X-100 in PBS for 10 minutes and 
blocked in 4% BSA, 0.3% Triton in PBS for 30 minutes. They were then incubated 
in a primary antibody (rabbit anti-53BP1, Cambridge Bioscience; rabbit anti-
pH2AX, Cell Signaling Technology) in blocking solution at 4oC overnight at a 
dilution of 1:250. The secondary antibody (AlexaFluor 555 Goat anti-Rabbit, Life 
Technologies) was applied for 2 hours at 1:200. Sections were stained with the 
fluorescent Nissl stain NeuroTrace 500/525 (Life Technologies) at 1:50 for 30 
minutes and DAPI (Life Technologies) at 1:1000 for 5 minutes before mounting in 
Mowiol (Sigma). Images of motor neurons within the thoracic region of the spinal 
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cord and within the facial nuclei of the brainstem were captured on a confocal 
microscope (Nikon A1R FLIM) at a 40x magnification.  
 
For neuromuscular junction (NMJ) labelling, muscles were removed from recently 
sacrificed mice and fixed in 4% PFA (Electron Microscopy Science) in PBS for 15 
minutes. Muscles were permeabilised in 2% Triton X-100 for 30 minutes and 
blocked in 4% BSA, 1% Triton for 30 minutes before incubation in primary 
antibodies (Neurofilament (2H3) and Synaptic vesicle protein 2 (SV2), both at 1:50, 
Developmental Studies Hybridoma Bank) at 4oC on a rocking platform for 4 days. 
Following two 10 minute PBS washes, muscle were immersed in α-Bungarotoxin at 
1:200 for 2 hours to label Post-synaptic Acetylcholine receptors and subsequently the 
secondary antibody (Cyc3 Goat anti-Mouse, Jackson) at 1:250 overnight. Muscles 
were washed in PBS and mounted in Mowiol (Sigma). NMJs were imaged on a 




Fiji Image Processing Software was used to analyse images of motor neurons. 
Images were blinded to ensure there was no knowledge of whether the image was 
from brainstem or spinal cord sections. All analysis was carried out in grayscale. 
Motor neurons were distinguished from other neuronal material by their large size 
and irregular shape. Only motor neurons that conformed to this criterion and had a 
visible nucleus were analysed. The maximum staining intensity for P53BP and 
pH2AX was measured by tracing the periphery of each motor neuron and instructing 
the software to measure the mean grey value of the area within. 
 
Microsoft Excel (Mac 2011) was used to collate the measurement information and 
this was subsequently analysed in GraphPad Prism (Version 6 for Mac OS X). All 
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Injection with Pifithrin-α 
 
A 20mg/ml Pifithrin-α and DMSO (Dimethyl Sulfoxide) solution was diluted to 
0.6mg/ml in Saline. Mice were injected with 2mg/kg of the solution via 
intraperitoneal injection daily from P5–P9. Untreated mice received a daily injection 
of 0.6mg/ml solution of DMSO only. Treated and untreated mice were sacrificed 1 
hour after the final injection and spinal cords were immediately removed. These 
were snap frozen and stored at -80oC.  
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Chapter 3: Investigating transcriptional differences between differentially 




SMA is caused by a mutation or deletion of the SMN1 gene, which results in a 
reduction of SMN protein.3,4 The exact function of this ubiquitously expressed 
protein is currently unknown however, there are various suggested functions of 
SMN. 
 
SMN is known to be involved in pre-mRNA splicing, which is a process whereby 
non-coding introns are removed from pre-mRNA and the exons are rejoined to allow 
translation to progress.24 This is facilitated by the spliceosome, which consists of a 
variety of components. One of the components is snRNPs (small nuclear ribonuclear 
proteins) and, in vivo, SMN is important in the assembly of these. In this role, Smn 
exists as a complex that comprises of SMN and several Gemin proteins, Gemin 2-
7.25 The SMN complex can then bind Sm proteins and together with snRNAs (small 
nuclear RNAs) they create snRNPs.25 There are both major and minor spliceosomes. 
These differ in their composition of snRNAs and minor spliceosomes are thought to 
be responsible for splicing only ~1% of transcripts.26,27 However, minor splicosomes 
are more affected by a reduction in SMN and therefore, although there may only be a 
small number of splicing defects, these may affect RNAs that are particularly 
important in motor neurons.26,28 Thus explaining the selective vulnerability of motor 
neurons. 
 
However, it has been suggested that SMN’s role in splicing is not the causative 
factor of the SMA phenotype and instead splicing defects are a consequence of the 
disease.29 This is since the majority of splicing products are similar in SMA mouse 
models and wild type mice until later on in the disease progression.29 Therefore, 
other functions of SMN that, when disrupted, could cause SMA have been 
suggested. For example, roles in axonal transport of RNA or in actin dynamics have 
been proposed.30,31  
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Although it is clear that a reduction in SMN disrupts many cellular processes, it is 
still not clear which of these disrupted processes contributes to the degeneration of 
motor neurons. It is also not clear why not all motor neurons degenerate and some 
appear to be resistant to degeneration. This phenomenon is observed in both patients 
and SMA mouse models.32,9 SMA patients experience progressive paralysis in the 
muscles of their trunk and limbs due to denervation, however proximal limb muscles 
are more affected than distal muscles.32 In addition, the diaphragm and facial 
muscles remain innervated, with facial weakness being seen in only very severe 
cases.32 In Amyotrophic Lateral Sclerosis (ALS), another type of Motor Neuron 
Disease, this is also seen as eye movements are preserved in severe ALS patients.33 
SMA mouse models also display this differential vulnerability of motor neurons. In 
the severe mouse models of SMA, abnormal NMJs and denervation is visible in 
abdominal muscles whilst specific cranial muscles (the rostral band of the Levator 
Auris Longus and Adductor Auris Longus muscles34) lack these features, even late 
on in the disease progression.9,13 This differential vulnerability between abdominal 
and cranial muscles is even more distinct in the intermediate Smn2B/- mouse model of 
SMA.20,35 
 
In the work by Murray et. al. (Acta Neuropathol. Commun., In Press), that was 
described in the introduction to this thesis, transcriptional profiles of differentially 
vulnerable motor neurons in the Smn2B/- mouse model of SMA and wild type mice 
were compared. By filtering for transcriptional changes that occurred in the 
comparison of Smn2B/- and wild type vulnerable motor neurons and in the 
comparison of Smn2B/- and wild type resistant motor neurons, transcriptional changes 
that correlated with a reduction in SMN could be highlighted (Figure 1; blue arrows). 
This provided an insight into the pathways that are disrupted by a reduction in SMN. 
They noted that transcripts involved in rRNA binding and in ubiquitination were 
down-regulated in both Smn2B/- vulnerable and resistant motor neurons compared to 
their wild type counterparts. In addition, transcripts involved in cell death pathways 
were up-regulated in vulnerable motor neurons of the Smn2B/- mouse compared to 
their counterparts in wild type mice. Although this up-regulation in cell death 
transcripts did not appear in the comparison of resistant motor neurons of Smn2B/- and 
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wild type mice, it was of particular interest due to the pre-symptomatic time point at 
which this up-regulation was observed.  
 
Murray et. al. also looked for changes that occurred between vulnerable and resistant 
motor neurons. This was done by comparing vulnerable Smn2B/- motor neurons to 
resistant Smn2B/- motor neurons and to wild type vulnerable motor neurons (Figure 1; 
red arrows). They noted that transcripts involved in DNA repair were up regulated in 
resistant motor neurons compared with vulnerable motor neurons suggesting that this 
provides them with some level of protection (Figure 1; red arrows).  The 
transcriptional changes that occurred between these motor neurons could provide an 
insight into why some motor neurons are resistant to degeneration and others are not. 
 
In this chapter, I aimed to detect transcriptional changes that were identified by 
RNAseq by either qRT-PCR or immunofluorescence. Firstly, transcripts that are 
altered by a reduction in SMN were investigated. I aimed to detect the changes in 
transcripts implicated in rRNA binding, ubiquitination and cell death in whole spinal 
cord cDNA using qRT-PCR. Based on the result from the RNAseq screen, we 
hypothesized that we would detect changes in transcripts involved in these cellular 
processes. Although changes in transcripts involved in ubiquitination and cell death 
between wild type and Smn2B/- mice were detectable by qRT-PCR, changes in 
transcripts involved in rRNA binding could not be detected. Secondly, transcripts 
that may provide motor neurons with resistance against degeneration were 
investigated. I aimed to detect alterations in DNA repair between vulnerable and 
resistant motor neurons using immunofluorescence against protein markers of DNA 
repair. The intensity of fluorescence staining was quantified to provide an indication 
of the level of DNA repair taking place in different motor neurons. Based on the 
results of the RNAseq screen, we hypothesized that motor neurons in the brainstem 
would have an increased intensity of staining for these DNA repair markers. 
Following analysis of staining, there was no significant difference between the 
staining intensity of brainstem motor neurons compared with spinal cord motor 
neurons. 
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Firstly, transcripts identified by RNAseq as being altered by a reduction in SMN 
were investigated. Using qRT-PCR transcripts in the whole spinal cord of Smn2B/- 
mice and wild type mice were compared. In order to investigate whether 
transcriptional changes can be detected by qRT-PCR, primer sets specific for 
transcripts being investigated were sourced. A variety of pre-optimized and custom-
made primers were used. Custom made primers had to be optimized before use to 
establish whether they were specific and quantitative. Where primers were deemed 
not suitable, due to not having the correct efficacy or product size (see below), pre-
optimized primers were purchased. Figure 2 displays the process of optimization 
carried out for primers, using the housekeeping gene PPIA as an example. To 
identify the optimal annealing temperature, we performed a gradient qRT-PCR in 
which the annealing temperature was varied.  In this example, primers were directed 
against PPIA and cDNA samples were exposed to 8 different annealing temperatures 
ranging from 55oC to 65oC (Figure 2A).  The curve that has the lowest Ct (cycle 
threshold) value and therefore crosses the threshold first, corresponds to the sample 
that was exposed to the optimum temperature for a given primer set. For PPIA this 
temperature was 64.5oC. This is the temperature at which the greatest volume of 
PPIA product is generated in the fewest cycles and therefore is the annealing 
temperature that will be used for all subsequent qRT-PCR experiments involving this 
primer set. In order to assess the efficiency of the primers directed against PPIA, a 
standard curve was created. A standard curve plots the log of the starting volume of 
cDNA against the Cq (quantitation cycle) value, which is reflective of the level of 
fluorescence detected (Figure 2B). To produce varying log values a dilution series of 
cDNA, of which the concentrations of cDNA are known, was set up. The standard 
curve is a linear graph and its gradient will determine the efficacy of the primer set. 
The efficacy of the primer should lie between 90-110% and therefore, with the value 
of 94.5%, PPIA primers have an appropriate efficiency for future use. In order to 
confirm that the product produced was the desired target, the size of the amplified 
product was determined. Gel electrophoresis revealed the length of the product of 
PPIA was 150 base pairs (Figure 2C). This was the expected length of the product, 
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due to the distance between the binding sites of the forward and reverse PPIA 
primers.  Together this analysis shows that these primers have an optimal annealing 
temperature of 64.5oC, have an efficiency within the desired limits and produce a 
produce of expected size.  Based on this data, these PPIA primers were deemed 
appropriate for use in quantitative experiments.  The same procedures were repeated 
for all primer sets used.  
 
Following optimization, suitable primers were used to investigate, by qRT-PCR, 
transcriptional changes that correlated with reduced SMN levels. Whole spinal cord 
cDNA of P10 (pre-symptomatic) Smn2B/- and wild type mice was used rather than the 
cDNA derived from laser captured (LCM) motor neuron cell bodies that was used by 
Murray et. al. (Acta Neuropathol. Commun., In Press). The level of some transcripts 
in LCM cDNA samples is too low to be detected by qRT-PCR and amplification of 
the cDNA samples to increase the levels of these transcripts introduced qRT-PCR 
inhibitors that interfered with the qRT-PCR reaction. Whole spinal cord cDNA can 
be used in this situation as the comparison of distinct motor neuron pools is not 
Figure 2: Custom-made primer sets were optimized before use. Here, the optimization 
of PPIA acts as an example to show the protocol used to optimize all custom-made primer 
sets. (A) The curves on this graph are created by plotting the fluorescence intensity of 
samples against the number of amplification cycles. Samples had the same starting 
volume of cDNA but were exposed to various annealing temperatures. The curve that 
crosses the horizontal, threshold line first denotes the sample exposed to the optimum 
annealing temperature. For PPIA, this was 64.5oC (RFU = relative fluorescence units). (B) 
A standard curve is created by plotting the fluorescence intensity against the log of the 
starting quantity of cDNA. A dilution series of cDNA (dilution factor = 1:5) creates 
varying starting concentrations. These are exposed to the optimal annealing temperature 
for PPIA. The standard curve reveals the efficacy of the primer set. An efficacy between 
90-110% is desirable. PPIA had an efficacy of 94.5% (quantitation cycle). (C) The 
product length of PPIA was as expected, approximately 150bp. 	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necessary to detect transcriptional changes that correlate with SMN reduction, rather 
the comparison of spinal cord tissue is sufficient.  
 
One of the top functional clusters that was identified during the previous RNAseq 
screen was ‘ribosome and rRNA binding proteins’.  Transcripts, including MRPL20 
(mitochondrial ribosomal protein L20) and RPS27A  (ribosomal protein S27a), were 
previously shown to be down-regulated in cell bodies of Smn2B/- mice compared with 
wild type.15 Since MRPL20 and RPS27A had a relatively high fold change in 
regulation, they were used to investigate whether transcriptional changes can be 
detected by qRT-PCR. qRT-PCR showed there was no significant difference 
between the transcript levels of both MRPL20 and RPS27A  in Smn2B/- mice 
compared to wild type mice (Figure 3). This result implies that either the change in 
transcript levels are too small to be detected by qRT-PCR on whole spinal cord 
cDNA or that this change, which was detected by RNAseq, is not consistent in new 
biological replicates.  
Murray et. al. (Acta Neuropathol. Commun., In Press) also showed that the 
ubiquitination pathway was down-regulated in the Smn2B/- mouse model. We 
therefore investigated the transcript levels of Ubiquitin (UBB) by qRT-PCR. This 
Figure 3: There is no change in transcripts associated with rRNA binding in 
Smn2B/- mice at a pre-symptomatic stage. qRT-PCR analysis was used to compare the 
transcript levels of MRPL20 and RPS27A  in cDNA from Smn2B/- and control (WT) mice 
at P10 (pre-symptomatic). (A) Bar chart (Mean ± SEM) shows that the relative 
normalized expression of MRPL20 is not significantly changed in Smn2B/- mice 
compared to controls at P10 (B) Bar chart (Mean ± SEM) shows that the relative 
normalized expression of RPS27A is not significantly changed in Smn2B/- mice compared 
to controls at P10 (By Mann Whitney U Test; n=4 mice per genotype). 
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showed that UBB was significantly down-regulated in the Smn2B/- mouse model 
compared to wild type mice (Figure 4) and therefore is in agreement with the 
RNAseq results. This suggests that the functional cluster of ubiquitination is down-
regulated in the Smn2B/- mouse model of SMA and therefore may be involved in 
SMA.  This is consistent with previous reports describing defects in ubiquitination in 





Furthermore, the RNAseq by Murray et. al. (Acta Neuropathol. Commun., In Press) 
showed an up-regulation of transcripts involved in cell death, specifically the P53 
signaling pathway. FAS, CDKN1A (Cyclin-Dependant Kinase Inhibitor 1A) and 
PMAIP1 (Phorbol-12-Myristate-13-Acetate-Induced Protein 1) are all involved in 
this signaling pathway and again they all showed a high fold change between Smn2B/- 
and wild type mice. Therefore, they were investigated by qRT-PCR. This revealed 
that all three transcripts were significantly up-regulated in the Smn2B/- mouse 
compared to wild type mice (Figure 5). As above the up-regulation of these 
transcripts in the Smn2B/- mouse model may suggest that pathways involved in cell 
death may be up-regulated at pre-symptomatic stages in SMA models.  
 
Figure 4: There is a down-regulation of 
Ubiquitin in Smn2B/- mice at a pre-symptomatic 
stage. qRT-PCR analysis was used to compare the 
transcript levels of Ubiquitin (UBB) in cDNA from 
Smn2B/- and control (WT) mice at P10 (pre-
symptomatic).  Bar chart (Mean ± SEM) shows that 
the relative normalized expression of UBB is 
significantly down regulated in Smn2B/- mice 
compared to wild type controls at P10 (*P<0.05 by 
Mann Whitney U Test; n=4 mice per genotype). 
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The data above demonstrates that some transcriptional changes can be detected by 
qRT-PCR. Therefore, the changes that were detectable were further investigated in 
the more severe Smn-/-;SMN2(tg/0) mouse model of SMA. This would clarify whether 
these changes are exclusive to the Smn2B/- model or whether they appear to be 
universal in SMA mouse models. Whole spinal cord cDNA of pre-symptomatic (P2) 
Smn-/-;SMN2(tg/0) mice and control littermates was used for analysis. It was observed 
that UBB was significantly down-regulated in the Smn-/-;SMN2(tg/0) mouse model 
compared to controls (Figure 6). Additionally, even though CDKN1A was not 
significantly different between Smn-/-;SMN2(tg/0) mice and controls, FAS and PMAIP1 
were significantly up-regulated in this severe SMA mouse model (Figure 7). 
 
Figure 5: There is an up-regulation of transcripts involved in cell death in Smn2B/- 
mice at a pre-symptomatic stage. qRT-PCR analysis was used to compare the transcript 
levels of CDKN1A, FAS and PMAIP1 in cDNA from Smn2B/- and control (WT) mice at 
P10 (pre-symptomatic). Bar charts (Mean ± SEM) show that the relative normalized 
expression of CDKN1A (A), FAS (B) and PMAIP1 (C) are all significantly up-regulated in 
Smn2B/- mice compared to wild type controls at P10 (*P<0.05, ***P<0.001 by Mann 
Whitney U Test; n=4 mice per genotype).  
	  
Figure 6: There is a down-regulation of 
Ubiquitin in Smn-/-;SMN2(tg/0) mice at a 
pre-symptomatic stage. qRT-PCR analysis 
was used to compare the transcript levels of 
UBB in cDNA from Smn-/-;SMN2(tg/0) and 
control (Smn+/+;SMN2(tg/0)) mice at P2 (pre-
symptomatic).  Bar chart (Mean ± SEM) 
shows that the relative normalized expression 
of UBB is significantly down regulated in 
Smn-/-;SMN2 mice compared to controls 
(*P<0.05 by Mann Whitney U Test; n=3 
mice per genotype). 
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Secondly, transcripts that may provide motor neurons with resistance against 
degeneration were investigated. DNA repair was highlighted, by Murray et. al. (Acta 
Neuropathol. Commun., In Press), as a functional cluster that could provide 
resistance to degeneration as there was a greater level of transcripts involved in DNA 
repair in resistant motor neurons compared to vulnerable motor neurons. Further 
investigation into DNA repair was carried out using immunofluorescence rather than 
qRT-PCR as resistant and vulnerable motor neuron pools are within the same mouse. 
As they are in different regions of the mouse and these regions, the brainstem and 
spinal cord, contain a different concentration of motor neurons, performing qRT-
PCR on the whole tissues would not give an accurate representation of 
transcriptional differences within the motor neurons. Previous attempts have been 
made to perform qRT-PCR on transcripts involved in DNA repair on laser captured 
motor neurons.  However, the relative abundance of these transcripts made this 
technically extremely challenging.  Instead, brainstem and spinal cord sections were 
stained for markers of DNA repair by immunofluorescence. Markers of DNA repair 
include pH2AX (phosphorylated Histone H2A family member X) and P53BP (P53 
Binding Protein). 
Figure 7: There is an up-regulation of transcripts involved in cell death in Smn-/-
;SMN2(tg/0)  mice at a pre-symptomatic stage. qRT-PCR analysis was used to compare 
the transcript levels of CDKN1A, FAS and PMAIP1 in spinal cord cDNA from Smn-/-
;SMN2(tg/0)  and control (Smn+/+;SMN2(tg/0)) mice at P2 (pre-symptomatic).  (A) Bar 
chart (Mean ± SEM) shows that the relative normalized expression CDKN1A was not 
significantly altered in Smn-/-;SMN2(tg/0) mice. Bar charts (Mean ± SEM) for FAS (B) and 
PMAIP1 (C) show that the relative normalized expression of these transcripts are both 
significantly up regulated in Smn-/-;SMN2(tg/0) mice compared to controls at P2 (*P<0.05 
by Mann Whitney U Test; n=3 mice per genotype).	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H2AX is phosphorylated (creating pH2AX) at sites of DNA damage early after 
damage has occurred to attract other important factors to the site in order to facilitate 
DNA repair.37 It can therefore provide information about the amount of DNA repair 
occurring.38 Motor neurons of the brainstem and spinal cord were stained for pH2AX 
and were counterstained with florescent Nissl and DAPI (Figure 10A). They were 
imaged on a confocal microscope and captured images were analysed in Fiji Imaging 
Software. Since images of pH2AX, Nissl and DAPI staining of each motor neuron 
could be separated, tracing of motor neurons could be carried out using Nissl staining 
as a guide on one channel and the intensity of pH2AX staining could be measured on 
another channel. The intensity is measured as mean grey value. A greater mean grey 
value indicates a greater level of protein. Mean grey values from motor neurons in 
the spinal cord and brainstem were collated. An unpaired T-test of the mean grey 
values of motor neurons in the spinal cord and brainstem showed there was no 
statistically significant difference in intensity between these two motor neuron 
populations (Figure 10B). In order to investigate whether there was significant inter-
mouse variability in the levels of DNA repair that could mask potential differences 
between neuronal populations, the average of the mean grey values for the spinal 
cord and brainstem of each mouse was subjected to a paired T-test. This was also not 
statistically different (Figure 10C). 
 
pH2AX can also be assessed by counting bright foci within the nucleus of cells.38 
However, bright foci were difficult to count in the staining produced here therefore, 
the intensity of staining within each motor neuron was categorised into ‘negative’ 
(no staining apparent), ‘faint’, or ‘bright’. Once collated each category was subjected 
to a paired t-test to compare, for example, the amount of faintly stained motor 
neurons in the spinal cord to the amount of faintly stained motor neurons in the 
brainstem. There was no significant difference in negative, faint or bright staining of 
pH2AX between the brainstem and spinal cord (Figure 10D). Overall, the results 
suggest that pH2AX is not altered between motor neurons of the spinal cord and 
brainstem. 
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P53BP also appears early at sites of DNA repair following DNA damage and mice 
that are deficient in this protein are unable to elicit normal DNA repair 
mechanisms.39,40 Therefore, P53BP can serve as another marker of DNA repair and 
the methods used to analyse pH2AX were repeated for P53BP. Motor neurons of the 
brainstem and spinal cord were stained for P53BP and were counterstained with 
florescent Nissl and DAPI (Figure 11A). Mean grey values of P53BP staining in 
motor neurons were collated. An unpaired T-test of the mean grey values of P53BP 
staining in motor neurons of the spinal cord and brainstem showed there was no 
Figure 10: The intensity of pH2AX 
staining is not significantly different 
between vulnerable and resistant 
motor neurons. (A) Confocal images of 
motor neurons in the brainstem and 
spinal cord stained with a primary 
antibody against pH2AX (Red). The 
Nissl staining (Green) labels neurons and 
DAPI (Blue) labels nuclei. Images are 
from P10 wild type mice. 273 and 278 
motor neurons were counted in the SC 
and BS respectively (Scale Bar = 50𝜇m). 
(B) The scatterplot (Mean±SEM) of pH2AX staining in motor neurons of the spinal cord and brainstem. There is no 
significant difference. (C) The average of the mean grey value for the spinal cord and 
brainstem of each mouse is plotted on the graph (Mean±SEM). The different symbols 
represent different mice. There is no significant difference between the staining in motor 
neurons of the spinal cord and brainstem (D) The intensity of pH2AX staining within motor 
neurons was rated as negative (if there was no staining), faint or bright. The bar chart 
collates these results showing the percentage of each category in the brainstem and spinal 
cord (Mean±SEM). There was no significant difference between negative, faint or bright 
staining of pH2AX between the brainstem and spinal cord (n= 4 mice). 
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statistically significant difference (Figure 11B). Again, to account for inter-mouse 
variability the average of the mean grey values for the spinal cord and brainstem of 
each mouse was subjected to a paired T-test. This was also not statistically different 
(Figure 11C). In keeping with the methods used for pH2AX, the intensity of P53BP 
was categorized into ‘negative’ (no staining apparent), ‘faint’, or ‘bright’. There was 
also no significant difference in negative, faint or bright staining of P53BP between 
the brainstem and spinal cord of each wild type mouse. 
 
(B) The scatterplot (Mean ± SEM) displays the mean grey values of P53BP staining in motor 
neurons of the spinal cord and brainstem. There is no significant difference. (C) The average 
of the mean grey value for the spinal cord and brainstem of each mouse is plotted on the graph 
(Mean±SEM). The different symbols represent a different mouse. There is no significant 
difference between the staining in motor neurons of the spinal cord and brainstem (D) The 
intensity of P53BP staining within motor neurons was rated as negative (if there was no 
staining), faint or bright. The bar chart collates these results showing the percentage of each 
category in the brainstem and spinal cord (Mean± SEM). There was no significant difference 
between negative, faint or bright staining of P53BP between the brainstem and spinal cord (n= 
3 mice).	  
Figure 11: The intensity of P53BP 
staining is not significantly different 
between vulnerable and resistant motor 
neurons. (A) Confocal images of motor 
neurons in the brainstem and spinal cord 
stained with a primary antibody against 
P53BP (Red). The Nissl staining (Green) 
labels neurons and DAPI (Blue) labels 
nuclei. Images are from P10 wild type 
mice. 190 and 200 motor neurons were 
counted in the SC and BS respectively 
(Scale Bar = 50𝜇m).  
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Firstly, transcriptional changes that correlate with a reduction in SMN were 
investigated in pre-symptomatic Smn2B/- and wild type mice, using qRT-PCR. A 
change in transcripts associated with ribosomal proteins between wild type and 
Smn2B/- mice could not be detected. However, qRT-PCR showed a down-regulation 
of ubiquitin transcript, involved in ubiquitination, and an up-regulation of transcripts 
involved in cell death in the Smn2B/- mouse model of SMA. These detectable changes 
were also shown to occur, by qRT-PCR, in pre-symptomatic Smn-/-;SMN2(tg/0) mice, 
a more severe mouse model of SMA. Secondly, DNA repair activity in differentially 
vulnerable motor neurons was investigated. There was shown to be no significant 
difference in DNA repair activity between resistant, brainstem motor neurons and 
vulnerable spinal cord motor neurons.  
 
Some transcriptional changes that had been noted to occur between wild type and 
SMA mice from previous RNAseq analysis, carried out by Murray et. al. (Acta 
Neuropathol. Commun., In Press), could not be detected by qRT-PCR. The previous 
RNAseq analysis was preformed on motor neuron cell bodies, obtained by LCM, not 
on whole spinal cord cDNA, perhaps explaining the obtained results. As stated 
earlier, LCM cDNA could not be used as the level of some transcripts in LCM 
cDNA samples is too low to be detected by qRT-PCR. Amplification of LCM cDNA 
samples to increase the levels of these transcripts introduced qRT-PCR inhibitors 
that interfered with the qRT-PCR reaction. Whole spinal cord cDNA could be used 
as the comparison of distinct motor neuron pools was not necessary to detect 
transcriptional changes that correlate with SMN reduction, rather the comparison of 
whole spinal cord tissue from a wild type mouse and a SMA mouse model is 
sufficient. However, motor neuron cell bodies make up a relatively small proportion 
of the entire spinal cord and the abundance of other cell types may mask the small 
transcriptional changes occurring in motor neurons. 
 
Transcripts associated with rRNA binding proteins, including MRPL20 and RPS27A, 
were not significantly altered in the qRT-PCR analysis. rRNA binding proteins are 
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ribosomal proteins that along with rRNA create the ribosomal subunit that is 
responsible for translation. Disruptions in translation have been linked to Spinal 
Muscular Atrophy with Respiratory Distress (SMARD), a disorder caused by 
mutations of the protein IGHMBP2 rather than SMN.41,42 Therefore, due to the 
importance of ribosomal proteins in translation, the down-regulation observed in the 
previous RNAseq results should not be over-looked. Therefore in the future, it may 
be interesting to investigate rRNA binding proteins themselves, perhaps by western 
blotting to provide quantification of the concentration of these proteins in the spinal 
cords of wild type and SMA mouse models. 
 
Ubiquitin (UBB) transcript was down-regulated in both the Smn2B/- and the Smn-/-
;SMN2(tg/0) mouse models of SMA. Ubiquitination involves the addition of ubiquitin 
to proteins to mark them for degradation.43 Perhaps the malfunction of this pathway 
may lead to the build up of proteins that should be degraded and in motor neurons 
they may disrupt the normal homeostasis, creating a toxic like effect. Wishart et. al. 
(2014) demonstrated that there is a build up of beta-catenin, a down-stream target of 
the ubiquitinaton pathway, in distal axons of SMA models and that inhibiting this 
pharmacologically can modify the SMA phenotype.36  
 
Transcripts involved in cell death, specifically the P53 signaling pathway, were 
significantly up-regulated in both the Smn2B/- and the Smn-/-;SMN2(tg/0) mouse models 
of SMA. It should be noted that this up-regulation in the cell body of motor neurons 
was at a pre-symptomatic time point, before any NMJ pathology is noticeable. It is 
not known whether the death of motor neurons in SMA is caused by defects at the 
NMJ inducing cell death or whether nuclear defects are to blame, with the NMJ 
simply being the most vulnerable part of the cell and therefore the first part with 
visible deformities.44 The confirmation that markers of cell death are up-regulated in 
two mouse models of SMA, pre-symptomatically, would support the latter belief. 
Furthermore, it has been shown that full length SMN protein has an anti-apoptotic 
effect while SMN∆7 does not and in fact SMN∆7 increases apoptosis.45 It is also 
known that P53 and SMN interact and it has therefore been suggested that by binding 
P53, SMN stops P53 from activating apoptosis.46 Thus, a lack of SMN could be 
Natalie	  L	  Courtney	   	   The	  University	  of	  Edinburgh	  
S1476172	   	   MScR	  2015	  
31 
causing an increase in P53 and its downstream transcripts. Why then are the effects 
of this not seen until at least 6 months old, in the case of Type 1 SMA? Perhaps this 
is due to apoptosis being important in the development of the CNS and it is not until 
the requirement of apoptotic mechanisms in the CNS is decreased that the abnormal 
apoptosis activation is obvious.47 In addition, it has been shown that caspases, which 
are important in apoptosis, can cleave SMN.45 Perhaps if SMN is cleaved it is no 
longer be able to bind P53, and P53 can subsequently activate cell death. However, 
this is speculation and in fact it is unclear whether cleaving SMN abolishes its anti-
apoptotic properties or whether it is the products created by cleaving SMN that can 
induce apoptosis.47 
 
It is known that DNA damage can enhance P53 activity.48 DNA repair mechanisms 
can detect and combat this damage and therefore, it would be possible that an 
increase in DNA repair could provide a level of resistance to cell death. Murray et. 
al. (Acta Neuropathol. Commun., In Press) showed that in resistant motor neurons there 
is an increase at the transcript level in DNA repair compared to vulnerable motor 
neurons. However, at the protein level, which was investigated here, there was no 
significant difference in DNA repair between resistant and vulnerable motor neurons. 
It is possible that although there is an increased level of transcript involved in DNA 
repair these are not translated into proteins as the regulation of gene expression 
continues even after transcription to ensure that protein homeostasis is maintained.49 
 
However, it must be considered that perhaps it is the method used to investigate 
DNA repair at the protein level in this investigation is not optimal. Here, the entire 
spinal cord and brainstem were stained and motor neurons within the facial nuclei 
and thoracic region were imaged. It may be that some motor neurons imaged do not 
innervate the specific muscles which were defined are being highly vulnerable or 
resistant. Murray et. al. (Acta Neuropathol. Commun., In Press) injected a tracer into 
differentially vulnerable muscles to mark the motor neurons that correspond to the 
specific muscles. When these were stained for pH2AX and the intensity measured, 
this showed a decrease in pH2AX in vulnerable motor neurons of the thoracic spinal 
cord. Therefore, future methods that will take this variability into consideration 
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should be developed to investigate other markers of DNA repair before discounting 
the theory that DNA repair may provide resistance in neurodegeneration.  
 
It should also be noted that wild type mice were used to analyse the brainstems and 
spinal cords for DNA repair markers rather than using an SMA mouse model. This 
allowed differences in these markers that normally occur between differentially 
vulnerable motor neurons to be studied to determine whether these differences may 
cause one cell to deal with additional stress, like a decrease in SMN protein, while 
another is unable to cope. Although there was no significant difference in these 
markers in the wild type mice at the protein level, it would still be interesting to 
further investigate DNA repair markers within SMA mouse models. It could be that 
the increased transcripts in resistant motor neurons are available and under the stress 
placed on these motor neurons in SMA the transcripts are translated into proteins.  
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There are various mouse models used in SMA research.50,23,51 One of these models is 
the Smn2B/- mouse model of SMA that was created by mutating the murine Smn gene 
to generate the Smn2B allele.21 This allele acts like SMN2, as the mutation is within 
exon 7, and when expressed on a null background it creates a mouse with a 
phenotype representative of SMA.20 In the original manuscript, the Smn2B/- mouse 
was described as being an intermediate mouse model of SMA with a life expectancy 
of around 28 days.20 It has a longer pre-symptomatic window in comparison to more 
severe mouse models, in which it displays a normal weight gain, making it 
indistinguishable from its littermates.20 It is not until approximately P14 that Smn2B/- 
mice display phenotypic features of SMA.20 At this point, they can be distinguished 
from littermates as their ears and tails look comparatively smaller and they weigh 
less.20 At P21, denervation and pre-synaptic swelling is evident in the NMJs of 
Smn2B/- mice.20 Furthermore, as in other models of SMA and in SMA patients, there 
is also differential vulnerability of muscles in Smn2B/- mice, with some muscle 
showing large amounts of these NMJ abnormalities and others showing very little or 
even no NMJ abnormalities.20 
 
The Smn2B/- mouse model of SMA was used for the work presented in Chapter 1 as it 
had been used by Murray et. al. (Acta Neuropathol. Commun., In Press) in the work 
previously described. This model was used as they were able to make use of its 
prolonged pre-symptomatic period, in which NMJs remain intact, to utilise 
retrograde transport, whereby molecules are transported from the NMJ, along the 
axon and into the cell body. A tracer was injected into specific muscles and taken up 
by motor neurons at the NMJ. It was transported along the axon to highlight the cell 
bodies of motor neurons that correspond to these muscles.  
 
In Chapter 1, it was shown by qRT-PCR that transcripts involved in cell death were 
up-regulated in both the Smn2B/- and the Smn-/-;SMN2(tg/0) mouse models of SMA pre-
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symptomatically. As previously mentioned, this is of interest due to this up-
regulation occurring before any NMJ pathology is observed. This may suggest that 
the activation of cell death pathways, in the cell body, are causing NMJ pathology 
rather than the NMJ pathology causing the death of the cell.  
 
In this chapter, I aimed to investigate the timing of cell death pathway activation in 
the Smn2B/- mouse model of SMA. To do this the Smn2B/- mouse model had to be re-
derived, as this model was not available within our laboratory. The re-derived litter 
was created by crossing Smn+/- mice, which were on a FVB background, with 
Smn2B/+ mice, which were on a C57BL6J background. Before use in experimental 
work, our Smn2B/- mice were characterised.  Characterisation involved assessing 
phenotypic features and weight trends of the mice as well as analysing NMJ 
morphology at end stage of the disease and at P7. At this time point there was no 
evidence of morphological defects. However, the levels of key transcripts in the P53 
signalling pathway revealed a significant up-regulation at P7. Finally, we attempted 
to optimise a dosing regime for the P53 inhibitor Pifithrin-𝛼 (PFT). This will allow 
for future efforts dedicated to investigating whether inhibition of the P53 signalling 
pathway can impact upon NMJ pathology.   
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The steps involved in the re-derivation of the Smn2B/- mouse model of SMA can be 
seen in Figure 14. Firstly, Smn2B/+ mice on a C57BL6J background were imported 
from the Kothary Laboratory and were crossed with C57BL6J wild type mice to 
produce Smn2B/+ and Smn+/+ mice. This allowed the colony to be expanded using the 
Smn2B/+ mice. It also created the opportunity to optimise the genotyping protocol in 
our laboratory. PCR and gel electrophoresis amplified and separated DNA fragments 
that represented the Smn2B allele or murine Smn. While Smn2B/+ mice displayed two 
bands, the Smn2B allele of 700bp and the murine Smn of 500bp, Smn+/+ mice have 
only murine Smn and therefore were represented by one 500bp band (Figure 15A). 
Smn2B/+ mice were subsequently crossed together to produce a litter containing 
Smn2B/+, Smn2B/2B and Smn+/+ mice. Genotyping revealed Smn2B/+ mice and these 
were bred with Smn+/- mice on the FVB background, giving a litter that contained 
mixed background Smn+/+, Smn+/-, Smn2B/+ and Smn2B/- mice. Genotyping this litter 
involved two steps. Firstly, the 2B genotyping protocol differentiated Smn2B/+ and 
Smn2B/- mice (Figure 15A). However, Smn+/- and Smn+/+ cannot be distinguished 
from this protocol as both display one 500bp band. Therefore, a protocol that 
amplifies the cassette that creates the null allele as well as amplifying murine Smn 
was subsequently performed (Figure 15B). Smn+/- mice display two bands, the 
murine Smn of 1050bp and the cassette of 950bp, whereas Smn+/+ mice display only 
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Figure 14: Re- derivation of the Smn2B/- mouse line. C57BL6J Smn2B/+ mice were 
imported from the Kothary Laboratory. These were crossed with C57BL6J mice, 
homozygous for murine Smn. This produced litters consisting of Smn2B/+ and Smn+/+ mice. 
Smn2B/+ mice were crossed together giving Smn2B/2B, Smn2B/+ and Smn+/+ mice. In this 
project, Smn2B/+, which were on a C57BL6J background, were crossed with Smn+/- mice, on 
a FVB background, to obtain a litter of Smn2B/-, Smn2B/+, Smn+/- and Smn+/+ mice. Smn2B/- is 
the desired SMA model while Smn+/+ mice can be used as wild type controls.  
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Characterisation of our Smn2B/- mice was subsequently carried out. The weights of 
our Smn2B/- mice and their littermates were tracked and subsequently plotted (Figure 
16A). The graphs show the Smn2B/- mice are indistinguishable from each other early 
in post-natal life. However, when phenotypic features become apparent, weight gain 
in the Smn2B/- mice stalls and their weight decreases. Distinguishing features include 
small ears and a short tail, which are not obvious until approximately P12 (Figure 
16B). 
Figure 15: PCR and gel 
electrophoresis reveals the genotypes 
of mice in the re-derived Smn2B/- line. 
(A) The first PCR differentiates 
between Smn2B/- and Smn2B/+ (top band 
= 700bp Smn2B allele; bottom band = 
500bp murine Smn). (B) The second 
PCR differentiates between Smn+/- and 
Smn+/+ mice (top band = 1050bp 
murine Smn; bottom band = 950bp null 
Smn allele [primers bind the cassette 
that is inserted into the Smn gene to 
render the gene non-functional]).  
Figure 16: Phenotype of re-derived Smn2B/- mouse model of SMA. Smn2B/- mice show 
similar weight trends and phenotypic features as the previous Smn2B/- model. (A) The graph 
shows the weights of mice in a re-derived Smn2B/- litter. Note the divergence of weights from 
P12. When weighed, it was noted which mice displayed SMA features (small ears and a small 
tail), these are denoted by red squares. (B) Images show the differences between a Smn2B/- 
mouse and a wild type littermate. Note the abnormal ears (white arrowhead), the shorter, 
darker tail (yellow arrowhead) and the size difference (Approximate sizes: WT body = 60mm, 
WT tail = 48mm; Smn2B/- body = 55mm, Smn2B/- tail = 30mm) Scale Bar = 2cm.  
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We next analysed the morphology of NMJs from our Smn2B/- mice. Whole mount 
abdominal muscles were stained with  𝛼-Bungarotoxin to label endplates and staining 
for Neurofilament and Synaptic Vesicle 2 protein labelled axons. Abdominal 
muscles were used due to their accessibility and their thickness, which is small 
enough to permit staining and imaging of the entire muscle. Furthermore, in various 
mouse models of SMA the abdominal muscles are vulnerable and display severe 
NMJ pathology.9,20 At P20, the Smn2B/- mice show denervation and pre-synaptic 
swelling in the Transversus Abdominis and Rectus Abdominis muscles, which is not 
apparent in wild type muscles (Figure 17). However, the NMJs of the Rectus 
Abdominis seemed to have more severe pre-synaptic swelling than the NMJs of the 
Transversus Abdominis. In general, NMJs of Smn2B/- mice display an immature 
appearance. Unlike the wild type NMJs that are mature and pretzel-like, the NMJs of 
Smn2B/- mice retain an immature, plaque-like appearance.52 However, at P7 Smn2B/- 
mice are pre-symptomatic and show no obvious signs of abnormal NMJ morphology 
in the Transversus Abdominis. There was no apparent denervation or pre-synaptic 
Figure 17:  The NMJs of our Smn2B/- mice show signs of denervation and pre-synaptic 
swelling at P20. Representative confocal micrographs show the transversus abdominis 
(TVA) and rectus abdominis (RA) muscles from wild type (WT) and Smn2B/- mice (2B/-), 
both P20. Endplates are labelled with α-Bungarotoxin (BTX; green) and antibodies against 
Synaptic Vesicle Protein 2 (SV2) and Neurofilament (NF) allow visualization of axons 
(red). Note the fully innervated, pretzel-like appearance of the mature endplates in the wild 
type compared to the plaque-like appearance of the endplates in the Smn2B/-. Denervation 
(white arrowhead), partial denervation (blue arrowhead) and pre-synaptic swelling (yellow 
arrowhead) can be seen. Scale bar = 50𝜇m. 
 
	  
Natalie	  L	  Courtney	   	   The	  University	  of	  Edinburgh	  
S1476172	   	   MScR	  2015	  
39 
swelling. At this age, Smn2B/- and wild type mice have immature NMJs. The NMJs in 
both mice have a plaque-like appearance and some remain poly-innervated.  
 
Since there was no obvious NMJ defects or phenotypic features of SMA at P7, this 
was used as a pre-symptomatic time point. Transcriptional analysis by qRT-PCR was 
performed at P7 to investigate whether there is an early up-regulation of transcripts 
involved in the P53 signalling pathway in our Smn2B/- mice. Whole spinal cord 
cDNA of Smn2B/- mice and wild type littermates was used to compare FAS, PMAIP1 
and CDKN1A transcripts. All three transcripts were significantly up-regulated in the 
Smn2B/- mouse model of SMA compared to their wild type littermates (Figure 19). 
This confirms previous results performed on a genetically distinct version of the 
Smn2B/- mouse model, demonstrating an up-regulation of factors involved in the P53 
signalling pathway at pre-symptomatic time points (see Figure 5&7).  Importantly, 
this analysis was performed at P7, indicating that cell death pathway activation can 
be detected prior to evidence of NMJ pathology.  Furthermore, this finding validates 
this model as an appropriate model to attempt to inhibit the activation of cell death 
pathways using PFT. 
Figure 18:  Transversus Abdominis 
NMJs of P7 Smn2B/- mice do not show 
signs of denervation or pre-synaptic 
swelling. Representative confocal 
micrographs show the transversus 
abdominis (TVA) from wild type (WT) 
and Smn2B/- mice (2B/-), both P7. 
Endplates are labelled with α-
Bungarotoxin (green) and antibodies 
against Synaptic Vesicle Protein 2 (SV2) 
and Neurofilament (NF) allow 
visualization of axons (red). At this age, 
endplates still have an immature, plaque-
like appearance in both wild type and 
Smn2B/- mice. Scale bar = 50𝜇m. 
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Several litters were treated between P5 and P9 with PFT and while one half of the 
litter received PFT, the other half acted as a control group. However, following 
retrieval of the spinal cords, genotyping revealed that there were no Smn2B/- mice in 
any of the treated litters. This was performed in 3 litters of mice and, although 
statistically unlikely, there were no Smn2B/- mice in any of the treated litters. For this 
reason, this work is on going and current efforts are dedicated at repeating this work 
in Smn2B/- mice. Once samples of cDNA from the spinal cord of treated and untreated 
Smn2B/- mice are acquired, qRT-PCR will compare the levels of transcripts involved 
in cell death between the two. This will assess whether PFT treatment can alter the 
regulation of cell death transcripts.   
Figure 19: There is an up-regulation of transcripts involved in cell death in Smn2B/- 
mice at a pre-symptomatic stage. qRT-PCR analysis was used to compare the transcript 
levels of CDKN1A, FAS and PMAIP1 in cDNA from Smn2B/- and control (WT) mice at P7 
(pre-symptomatic). Bar charts (Mean ± SEM) show that the relative normalized 
expression of CDKN1A (A), FAS (B) and PMAIP1 (C) are all significantly up-regulated in 
Smn2B/- mice compared to wild type controls at P7 (*P<0.05, ***P<0.001 by Mann 
Whitney U Test; n=4 mice per genotype).  
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The Smn2B/- mouse model of SMA has been re-derived, creating a Smn2B/- mouse on 
a mixed genetic background. This mouse model appears to have very similar features 
to the original Smn2B/- mouse that was on a pure genetic background.  These 
similarities are in phenotypic features, weight trends, NMJ pathology and regulation 
of cell death transcripts. Both models have small ears and tails and show a normal 
weight gain before reaching a point at which weight gain stops and weight begins to 
decrease.20 They both show denervation and pre-synaptic swelling at the NMJs 
within abdominal muscles and both have an up-regulation of transcripts involved in 
cell death, pre-symptomatically.20,15 
 
PFT was to be used to assess whether the levels of transcripts involved in cell death 
could be altered in Smn2B/- mice. PFT is a drug originally developed to provide a 
treatment to reduce the side effects of chemotherapy, which are mainly caused by 
apoptosis through the P53 signalling pathway.53 It has also been shown to decrease 
the activation of CDKN1A which occurs downstream of P53.53 Due to a lack of 
Smn2B/- mice within litters, it is still unknown whether PFT is able to decrease 
transcripts involved in cell death in the spinal cords of Smn2B/- mice. Therefore, the 
progression of this project will depend on the outcome of the experiments. If in the 
PFT trial that we aimed to carry out, PFT does not alter the levels of these transcripts 
in the spinal cords of Smn2B/- mice, it should be considered that either the dose of 
PFT administered is not effective or PFT does not successfully cross the blood brain 
barrier (BBB). The PFT dose used in this experiment was previously used in mice to 
reduce cancer treatment side effects and also to reduce cell death in neurons of the 
cerebral cortex.53,54 It is also known that when given to mice via intraperitoneal 
injection, PFT is detectable in the cerebrospinal fluid of mice after 30 minutes and 
therefore PFT is able to successfully cross the BBB.54 However, in order to 
investigate whether PFT is crossing the BBB in our mouse model, transcript levels in 
another tissue, muscle for example, in which PFT would be able to cross into, should 
be compared in treated and untreated mice. An alteration in transcripts in the muscle 
of treated mice would indicate that manipulating drug entry through the BBB, 
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perhaps pharmacologically, might be required for PFT to act on spinal cord tissue. 
Gyroxin, which alters the permeability of the BBB for a short period of time, could 
be considered for use.55 However, if the PFT trial showed that PFT can alter 
transcript levels in the spinal cord, Smn2B/- mice would be treated for a longer period 
of time and the impact of decreasing transcripts involved in cell death on NMJ 
pathology would be assessed.  
 
The lack of Smn2B/- mice is the main limitation of this study. Therefore, in the future, 
perhaps Smn2B/- mice should be created by crossing Smn+/- with Smn2B/2B mice. This 
would give a 50% chance of obtaining Smn2B/- mice, rather than the 25% chance that 
we had in this project. Although, there was only a 25% chance, the cross that was 
carried out for this project produced Smn+/+ mice and Smn2B/- mice in the same litter. 
These Smn+/+ littermates could then be used as wild type controls. Furthermore, the 
Smn2B/- mice were re-derived onto the FVB background and on this background mice 
are often more efficient breeders and have larger litter sizes.56 It was therefore 
expected that there would be a greater chance of having Smn2B/- mice within one 
litter. 
 
Overall, establishing the Smn2B/- mouse model within our laboratory was successful 
and it is a valuable model for future experimentation. The presence of abnormal NMJ 
morphology was confirmed and this correlates with disease onset and progression. 
The early up-regulation of cell death transcripts was also confirmed in our Smn2B/- 
mice pre-symptomatically, at P7. This is important as it suggests that the activation 
of cell death pathways may contribute to the degeneration of the motor neuron and 
therefore, warrants further investigation into this idea. 
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Chapter 5: Conclusions and Future Work 
 
There were two main parts to this project. Firstly, work was carried out to discover 
whether transcriptional differences between differentially vulnerable motor neuron 
populations that had been highlighted by Murray et. al. (Acta Neuropathol. Commun., 
In Press) through RNAseq were detectable by other methods. These methods 
included qRT-PCR and immunofluorescence. Transcriptional differences that 
occurred between pre-symptomatic (P10) Smn2B/- and wild type motor neurons were 
investigated by qRT-PCR. These transcripts included those involved in rRNA 
binding, ubiquitination and cell death. qRT-PCR detected a down-regulation of UBB, 
involved in ubiquitination, and  up-regulation of FAS, CDKN1A and PMAIP1, which 
are transcripts associated with cell death. There was no detectable difference in 
MRPL20 and RPS27A transcript levels, both associated with rRNA binding, between 
wild type and Smn2B/- mice by qRT-PCR. Transcriptional differences in DNA repair 
that had occurred between vulnerable and resistant pools of motor neurons, in both 
wild type and Smn2B/- mice, were investigated by immunofluorescence. Staining for 
markers of DNA repair and measuring the staining intensity could represent the level 
of DNA repair activity. There was found to be no significant difference in staining 
intensity between resistant, brainstem motor neurons and vulnerable, spinal cord 
motor neurons. 
 
Detecting these transcriptional differences by qRT-PCR or by immunofluorescence 
would strengthen the suggestion that alterations in these functional clusters do occur 
in the Smn2B/- mouse model. In turn, this could warrant further investigation into why 
or how these functional clusters may be impacting on SMA pathology. Detecting 
changes in not only one but two mouse models of SMA, the intermediate Smn2B/- 
mouse model and the severe Smn-/-;SMN2(tg/0) mouse model, suggests that these 
transcriptional changes are not exclusive to the Smn2B/- model but rather they may be 
universal to SMA mouse models and in fact could occur in patients.  
 
In particular, transcripts involved in cell death were up-regulated in both mouse 
models of SMA. This was pre-symptomatically and therefore before any NMJ 
pathology is apparent. This suggests that the activation of cell death pathways may 
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contribute to the degeneration of the motor neuron, with the NMJ simply being the 
most vulnerable part of the cell and therefore the part where the effects of cell death 
activation are first observed. Preliminary work was carried out to begin investigation 
into this theory. We attempted to assess whether PFT can alter cell death transcripts 
in our Smn2B/- mouse model. The result from this would have established whether 
there is a possibility of PFT treatment impacting on NMJ pathology, perhaps 
reducing denervation or pre-synaptic swelling. The idea behind this experiment is 
that this may extend the pre-symptomatic period, which would in turn give a longer 
period of time in which therapeutics, perhaps those that restore SMN, could be 
administered. 
 
In the future, we first need to establish whether the current PFT dose can reduce the 
levels of cell death transcripts that are currently up-regulated in vulnerable Smn2B/- 
motor neurons by qRT-PCR. If PFT does alter cell death transcripts, then PFT should 
be administered for various lengths of time to assess the effects on NMJ pathology, 
specifically denervation and pre-synaptic swelling. Subsequently, if PFT is able to 
reduce NMJ pathology in Smn2B/- mice, we should consider investigating the 
possibility that down regulating cell death transcripts could extent the time window 
in which restorative SMN therapies can be given. SmnRes/Res mice (SMN2;SmnΔ7;Cre-
ER;SmnRes/Res) are an inducible SMA mouse model in which SMN production can be 
restored.57 Restoring SMN is most effective early on in the disease.57 However, if 
these mice were treated with PFT, is it possible that the time window that is effective 
for restoring SMN in order to alter the SMA phenotype would be extended? This 
idea should be investigated. By carrying out this work we would not only strengthen 
the theory that the early up-regulation of cell death pathways are the causative factor 
of NMJ pathology in SMA but also give valuable knowledge that could be used in 
the therapeutic treatment of SMA patients. 
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